At-Home Ketamine Treatment: A Complete System for Dosing, Monitoring, and Therapeutic Outcomes

For the first time, every essential component of clinician-directed at-home ketamine treatment is integrated into a single, measurable treatment model. It covers intranasal, sublingual or buccal, and subcutaneous racemic ketamine—from patient selection, individualized dosing, and pharmaceutical preparation to monitoring, rescue planning, recovery, and long-term evaluation of therapeutic outcomes.

The central principle is straightforward: Every decision that can be made before ketamine takes effect must be made in advance. Once ketamine alters attention, time perception, coordination, and judgment, patients should not be calculating doses, interpreting thresholds, or improvising treatment decisions. The dose, maximum session exposure, administration procedure, measurement schedule, stopping criteria, rescue medication, and level of support are therefore clearly established before treatment begins.

Three Routes With Fundamentally Different Effects

Racemic ketamine can be administered at home as a nasal spray, absorbed through the oral mucosa, or delivered by subcutaneous injection. These routes differ substantially in absorption rate, bioavailability, blood concentration, metabolite formation, and duration of effect. A 50-milligram dose therefore has a completely different pharmacological meaning depending on the route of administration.

Intranasal ketamine is absorbed relatively quickly and can be administered in predetermined portions. This makes it possible to withhold a later spray if blood pressure or psychological intensity has already increased significantly. The total dose is only one factor. The amount per spray, spray volume, administration technique, interval between sprays, nasal condition, and runoff into the throat all affect the actual exposure.

With sublingual or buccal ketamine, mucosal contact time, placement in the mouth, saliva handling, and whether the remaining medication is swallowed or expelled materially influence the resulting effect. A larger swallowed fraction is processed through the stomach, intestines, and liver, producing greater exposure to norketamine and other metabolites. This can change both the character of the experience and the duration of recovery. A change in administration technique can therefore have the same pharmacological significance as a change in dose.

Subcutaneous ketamine permits precise weight-based dosing and is absorbed rapidly. Once the injection has been administered, however, the dose can no longer be reduced. The medication concentration, injection volume, and total dose must therefore be fully established before treatment begins.

Individualized Dosing Instead of Standard Milligram Amounts

Every dose is documented both as an absolute amount in milligrams and as milligrams per kilogram of body weight. This is essential because, for example, 50 milligrams represents 1.0 mg/kg for a person weighing 50 kilograms but only 0.5 mg/kg for someone weighing 100 kilograms.

The goal is the lowest dose that produces a genuine therapeutic effect. A clearly perceptible or strongly dissociative experience is not automatically therapeutic. Conversely, successful treatment does not require the most intense possible alteration of consciousness. What matters is the change that follows the session: reduced depression, anxiety, or trauma-related distress; less fear of death; a changed relationship to existential concerns; improved quality of life; or greater emotional processing.

From Observed Initiation to At-Home Treatment

The first administration and every substantial dose increase should ideally occur under direct observation. This establishes the individual’s blood pressure and heart-rate response, dissociative intensity, susceptibility to nausea, behavioral response, and recovery time. At-home treatment then reproduces a previously observed and individually characterized process rather than introducing an unknown exposure.

This transition is particularly important because population averages cannot fully predict an individual patient’s response. Repeated documentation gradually creates a personal response profile that is considerably more informative than a standardized dose alone.

Clear Blood Pressure Thresholds and a Predetermined Rescue Procedure

Blood pressure and heart rate are measured after several minutes of rest before every session. If blood pressure remains at or above 150/100 mmHg, treatment does not begin. This clearly separates an elevated baseline from a later increase caused by ketamine.

During the active period, a reading at or above 180/110 mmHg triggers rest and repeated measurement. A single elevated reading does not automatically lead to medication. Three factors determine the response: the magnitude of the elevation, confirmation through repeated measurements, and persistence for approximately 15 to 20 minutes. This distinguishes a brief sympathomimetic peak from sustained severe hypertension.

If a blood pressure rescue medication has been prescribed for this situation, the medication, single dose, reassessment interval, and subsequent steps are established before the session. The patient never has to select a medication or calculate a dose while dissociated.

Psychological Intensity Is Not Automatically a Medical Emergency

Ketamine can produce intense fear, crying, emotional release, unusual thoughts, altered perception, temporary disorientation, and profound dissociation. These experiences can be highly intense while remaining part of an organized therapeutic process.

They must be clearly distinguished from acute manic or psychotic behavior, dangerous agitation, suicidal behavior, violent behavior, an unexpected major reduction in responsiveness, or loss of basic physical safety. These situations activate a separate, predefined escalation pathway.

During more intense sessions, a sober trusted adult performs clearly defined practical tasks. This person tracks time, records measurements, withholds any remaining staged doses when a threshold is reached, maintains a calm environment, and follows the written instructions. The support person is not expected to make a diagnosis or invent treatment decisions during the session.

Therapeutic Success Is Measured Over Days and Weeks

The intensity of the acute ketamine experience is not an adequate measure of success. Depression, anxiety, and post-traumatic stress are assessed alongside existential anxiety, fear of death, demoralization, loss of meaning, psychospiritual distress, and quality of life. Ketamine is therefore understood not only as a treatment for psychiatric diagnoses but also as a potential therapeutic approach to severe emotional and existential suffering.

Each session adds to an individualized profile of dose, route of administration, blood pressure response, heart rate, psychological effects, nausea, recovery time, and duration of therapeutic benefit. This information guides both dosage and treatment frequency. Following an initial treatment series, the intervals are gradually extended. The goal is not the most frequent possible administration, but the greatest therapeutic benefit at the lowest necessary dose and the longest effective interval.

The scientific article is published in the International Journal of Independent Research Studies:

Elias Rubenstein (2026): At-Home Racemic Ketamine Treatment: A Structured Framework for Preparation, Route-Specific Dosing, Monitoring, Rescue, Recovery, and Follow-Up
DOI: iu process

Elias Rubenstein. At-Home Racemic Ketamine Treatment: A Structured Framework for Preparation, Route-Specific Dosing, Monitoring, Rescue, Recovery, and Follow-Up.pdf